Zai Lab Limited Unsponsored ADR ZLAB
24.98
(0.30)
(1.19%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 0.0×
Follow ZLAB
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.72 | 4.60 | 4.20 | 8.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.47) | (174.87) | (74.25) | (116.56) | |
P/B ratio |
3.50 | 3.15 | 2.70 | 4.91 | |
Price to Tangible BV |
4.09 | 3.57 | 3.04 | 5.32 | |
EV/Sales |
3.65 | 3.39 | 2.93 | 7.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.32) | (15.20) | (8.93) | (17.29) | |
EV/FCF |
(10.11) | (11.57) | (8.21) | (14.84) | |
Quick Ratio |
1.84 | 2.07 | 2.15 | 2.51 | |
Current Ratio |
2.13 | 2.40 | 2.45 | 2.87 | |
Net Debt/EBITDA |
6.50 | 8.19 | 8.75 | 13.28 | |
Debt/Assets |
22.15% | 19.51% | 17.45% | 17.52% | |
Debt/Equity |
0.39 | 0.32 | 0.29 | 0.27 | |
Asset Turnover |
0.40 | 0.40 | 0.39 | 0.41 | |
Operating CF/Net income |
1.25 | 0.23 | 0.52 | 0.89 | |
Capex/Depreciation |
(0.52) | (8.74) | (0.50) | (1.57) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
58.10% | 65.85% | 48.30% | 41.28% | |
Selling, General and Administrative Expense of Revenue |
68.55% | 65.32% | 57.24% | 60.39% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.07 | 0.05 | |
Share Based Compensation of Revenue |
11.23% | 13.58% | 12.46% | 14.58% | |
Graham Net Nets |
0.21 | 0.25 | 0.29 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.00%) | (8.61%) | (9.13%) | (5.75%) | |
Free Cash Flow Yield |
(7.65%) | (6.37%) | (8.49%) | (5.63%) | |
Revenue per Share |
0.95 | 0.90 | 1.16 | 1.05 | |
Operating CF per Share |
(0.57) | (0.11) | (0.24) | (0.29) | |
Capex per Share |
(0.01) | (0.20) | (0.01) | (0.04) | |
Free Cash Flow per Share |
(0.58) | (0.31) | (0.25) | (0.33) | |
Cash per Share |
6.42 | 6.87 | 7.21 | 7.41 | |
Shareholders Equity per Share |
5.43 | 5.98 | 6.53 | 6.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.43 | 5.98 | 6.53 | 6.90 | |
Free Cash Flow |
(64.82) | (34.20) | (27.32) | (36.09) | |
Working Capital |
485.45 | 551.75 | 603.12 | 673.18 | |
Capital Expenditures |
(1.42) | (22.29) | (1.30) | (4.05) | |
Net Current Asset Value |
446.28 | 510.97 | 562.40 | 633.95 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.22 | 0.01 | 0.03 | |
Net Profit Margin |
(47.81%) | (51.22%) | (39.51%) | (30.98%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
79.05 | 65.31 | 95.65 | 67.67 | |
Average Payables |
122.02 | 114.59 | 121.26 | 110.18 | |
Average Inventory |
76.30 | 69.51 | 57.31 | 53.34 | |
Average Assets |
1,119.45 | 1,134.53 | 1,179.07 | 1,072.14 | |
Average Common Equity |
699.39 | 736.37 | 778.20 | 713.81 |
Columns are period end dates